¿Es frecuente la depresión mayor en la psoriasis?
DOI:
https://doi.org/10.29166/ciencias_medicas.v42i2.1494Keywords:
psoriasis, major depression, Beck test, degree of depression, PASI test, anxiety, suicidal ideasAbstract
Context: psoriasis is a dermatological pathology with important psychological consequences derived from the stigma generated by the striking appearance of the lesions, especially, isolation, anxiety, major depression and increase in suicidal ideas.
Objective: to determine the degree of depression in patients with the degree of severity of psoriasis.
Subjects and methods: a descriptive, cross-sectional study was conducted with random sampling in 82 patients with psoriasis, of both sexes, without previous diagnosis of depression, aged between 15 and 90 years, who attended the outpatient service of the Hospital’s Dermatology service. Carlos Andrade Marín, in the period July-August 2015. By means of the Beck test, the degree of depression and PASI index (Psoriasis Area Severity Index) was determined, the degree of psoriasis was estimated.
Results: the prevalence of depression was 24.4%; Statistical association was found between depression and severity of psoriasis. The female sex showed 3.5 times more risk to present depression with respect to the male sex; Subjects with severe psoriasis have a 35.7 times higher risk of depression compared with patients suffering from mild psoriasis.
Conclusion: the prevalence of depression is high and increases with the degree of severity of psoriasis, it is suggested to include in the routine management the psychological and psychiatric follow-up; it is recommended to implement prospective studies to determine the evolution of psychiatric comorbidities
in this population group, in order to design treatment protocols adjusted to the Ecuadorian population
Downloads
Metrics
References
Echeverri M, Londoño A, Velázquez M. Papel de las células Th17 en la inmunopatogénesis de la psoriasis. Rev Asoc Colomb Dermatol 2009; 17:3-9.
Schön MP, Boehncke. W. Psoriasis. N Engl J Med 2005; 352:1899-912.
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology 2014; 70(3):512-516.
Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005; 52(1):23-6.
Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013: 133:377.
Cañarte C, Cabrera F, Palacios S. Epidemiología de la psoriasis en el distrito Metropolitano de Quito. Revista de la Sociedad Ecuatoriana de Dermatología 2004; 2(1).
Feldman SR. (2015). Epidemiology, clinical manifestations and diagnosis of psoriasis. UpToDate2015.
González C, Londoño Á, Castro L. Guías basadas en la evidencia para el manejo de la psoriasis en Colombia.Editorial Panamericana 2012; 1-274.
Choi J, Koo JY. Quality of life issues in psoriasis. Journal of the American Academy of Dermatology 2003; 49(2):57-61.
De Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. Journal of Investigative Dermatology Symposium Proceedings 2004; 9(2):140-147.
Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14:485–496.
Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43:281–285.
Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. Journal of the American Academy of Dermatology 2006; 54(4):685–704.
Mukhtar R, Choi J, Koo JY. Quality-of-life issues in psoriasis. Dermatologic clinics 2004; 22(4):389-395.
Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41:401–407.
Gupta MA, Gupta AK, Ellis CN, Voorhees JJ. Some psychosomatic aspects of psoriasis. Adv Dermatol 1990: 5:21–30.
Zachariae R, Zachariae CO, Lei U, Pedersen AF. Affective and sensory dimensions of pruritus severity: associations with psychological symptoms and quality of life in psoriasis patients. Acta Derm Venereol 2008; 88:121–127.
Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000; 14:267–271.
Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms and interventions. Dermatol Clin 2005; 23:681–694.
Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG; National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal of the American Academy of Dermatology
; 58(6):1031-1042.
Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215:17–27.
Sharma N, Koranne RV, Singh RK. Psychiatric morbidity in psoriasis and vitiligo: a comparative study. Dermatol 2001; 419–423.
Akay A, Pekcanlar A, Bozdag KE, Altintas L, Karaman A. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 2002; 16:347–352.
Feldman SR. (2013). Treatment of psoriasis. UpToDate2013.
Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology 2005; 212(2):123-127.
Simen BB, Duman CH, Simen AA, et al. TNF-alpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry 2006; 59:775-85.
Adler UC, Marques Andrea H, Calil Helena M. Inflammatory aspects of depression. Inflammation & Allergy-Drug Targets 2008; 7(1):19-23
Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol BiolPsychiatry 2005; 29:201-17.
Ryan C, Korman NJ, Gelfand JM, et al. Research gaps in psoriasis: opportunities for future studies. Journal
of the American Academy of Dermatology 2014; 70(1):146-167.
Sociedad Latinoamericana de Psoriasis. (2009). Consenso Latinoamericano de Psoriasis. Guías de Tratamiento-Actualización 2009.
Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar D, Ferrándiz C, Puig L, Sánchez-Carazo JL. Abordaje integral de la comorbilidad del paciente con psoriasis. Actas DermoSifiliográficas 2012; 103:1-64.
Van Voorhees AS, Fried R. Depression and quality of life in psoriasis. Postgrad Med 2009; 121:154-61.
Declaración de Helsinki de la Asociación Médica Mundial (AMM). Principios éticos para las investigaciones médicas en seres humanos. 2013. Disponible en:http://www.wma.net/es/30pubÜcations/10poÜcies/b3/index.html
Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. International Journal of Methods in Psychiatric Research 2003; 12(1):3-21.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-71.
Steer RA, Cavalieri TA, Leonard DM, Beck AT. Use of the Beck Depression Inventory for primary care to
screen for major depression disorders. Gen Hosp Psychiatry 1999; 21(2):106-11.
Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A. Costs and quality of life for psoriatic patients at different degrees of severity in southern Swedenea cross-sectional study. Eur J Dermatol 2012; 22:238-45.
Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, et al. Economic burden of comorbidities in
patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 2011; 25:157-63.
Meyer N, Paul C, Feneron D, Bardoulat I, Thiriet C, Camara C, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010; 24:1075-82.
Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013; 149:1173-9.
Baughman R, Sobel R. Psoriasis: stress, and strain. Archives of Dermatology 1971; 103(6):599–605.
Fortune DG, Richards HL, Kirby B. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Archives of Dermatology 2003; 139(6):752–756.
Gaston L, Lassonde M, Bernier-Buzzanga J, Hodgins S, Crombez JC. Psoriasis and stress: a prospective study. Journal of the American Academy of Dermatology 1987; 17(1):82–86.
Habif TP. Textbook of Dermatology. 4ed. Londres:Elsevier Health Sciences; 2004.
Fortune DG, Richards HL, Main CJ, Griffiths CEM. What patients with psoriasis believe about their condition. Journal of the American Academy of Dermatology 1998; 39(2):196–201.
Griffiths CEM, Barker RD. Psoriasis en: Rook W, Wilkinsum Ebling. Textbook of Dermatology. : Blackwell Science; 2004.
Gutiérrez ZV, Medina J, García S, Betanzos A, Leyva Sartori M, Ontón Reynaga J, Rengifo Pinedo L, Reynoso G. Índice de severidad del área de psoriasis (PASI) en pacientes del Hospital Nacional Daniel Alcides Carrión durante el período 1996-2005. Dermatol Peru 2009;1 9(1):32-35.
Silva MT, Galvao TF, Martins SS, Pereira MG. Prevalence of depression morbidity among Brazilian adults: a systematic review and meta-analysis. Rev Bras Psiquiatr 2014; 36:262-270.
Cordero JD, Pacheco D. Prevalencia de la ansiedad, depresión y alcoholismo en estudiantes de medicina [tesis], Cuenca:Universidad del Azuay; 2010.
Cañarte C. Psoriasis. Fundación Ecuatoriana de la Psoriasis- FEPSO ECUADOR. Dermatologia Ibero-Americana Online 2010.
Hesham Abd El Moati Zaher, Mohammed Ezzat Amin, Mona Yehia Rakhawy. Coping with depression and anxiety In patients with psoriasis. Egypt J Psychiatry 2010; 31(2):57-63.
Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146(8):891-895.
Nasreen S, Ahmed I, Effendi S. Frequency and magnitude of anxiety and depression in patients with psoriasis vulgaris. J Coll Physicians Surg Pak 2008; 18:397-400.
Freire M, Rodríguez J, Möller I, Valcárcel A, Torneroe C, Díaz G, Armendáriz Y, Paredes S. Prevalencia de síntomas de ansiedad y de depresión en pacientes con artritis psoriásica en consultas de reumatología. Reumatol Clin 2011; 7(1):20–26.
Layegh P, Arshadi HR, Shahriari S, Pezeshkpour F, Nahidi Y. A Comparative study on the prevalence of depression and suicidal ideation in dermatology patients suffering from psoriasis, acne, alopecia areata and vitiligo. Iran J Dermatol 2010; 13:106-11.
Ayman E, Hanan N, Al Sadat M, Mona M, Majdy A, Wayne G. Depression over psoriasis: assessment of associated relief by addition of ADalimumab for the treatment of psoriasis: observational study (DORADOPs). Journal of Dermatology & Dermatologic Surgery 2015; 19:1-15.
